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Sorafenibis an oral angiogenetic multikinaseinhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding
and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We
report two cases of patients with hepatocellular carcinoma who developed a cerebrovascular accident while on sorafenib. Neither
patient had any risk factors for the cerebrovascular events apart from gender and age in the second patient. Laboratory data were
noncontributory. The head CT scan did not reveal acute abnormalities. No hemodynamically signiﬁcant stenosis was visible in
the carotid ultrasound, and the echocardiogram showed normal size of the heart chambers and normal systolic function of the
left ventricle. Sorafenib was discontinued in both cases. Physicians should monitor patients receiving sorafenib for neurologic
symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered.
1.Background
Sorafenib (trade name Nexavar, Bayer Pharmaceuticals,
Wayne,NJ,USA)isanorallyactivemultikinaseinhibitorthat
has been approved in the treatment of advanced hepatocel-
lular (HCC) and renal cell carcinoma [1]. Its antineoplastic
eﬀect is based on two main mechanisms: the inhibition
of both cell proliferation (by inhibiting Raf kinase) and
angiogenesis (by inhibiting VEGFR2, VEGFR3, and PDGFR-
β receptors) [2]. The approval of sorafenib in 2007 for the
treatment of HCC was based on the SHARP (Sorafenib
in Hepatocarcinoma Carcinoma Assessment Randomized
Protocol) study, a multicenter, phase III, double-blind,
placebo-controlled trial [3]. The most common adverse
reactions observed in patients receiving sorafenib included
constitutional symptoms, such as asthenia and fatigue,
dermatologic disorders such as hand-foot skin reaction, rash
andalopecia,aswell asgastrointestinal and liverdysfunction.
Hypertension of all grades was reported in 5% and 2% of
patients in the sorafenib and placebo group, respectively,
(P = .05). The diﬀerence in the incidence of grade 3
hypertension was not statistically signiﬁcant (2% versus
<1%, P = .28) and no grade 4 hypertension reported. The
incidences of cardiac ischemia or infarction were similar
(3% and 1%) [3]. When data from multiple clinical trials
on sorafenib were collected, hypertension crisis, cerebral
hemorrhage, myocardial infarction, andchronic heartfailure
were relatively uncommon (<1%) [4]. However, the docu-
mented association between angiogenic inhibitors, such as
bevacizumab [5] and sorafenib [6], and thromboembolic
and hemorrhagic events, dictates careful consideration dur-
ing sorafenib administration since the risk in such patients is
unknown.
We report two cases of patients with HCC who had
a cerebrovascular accident (CVA) while on sorafenib. We
studied their medical records to assess risk factors for
CVA, including age, sex, smoking, prior CVA, hypertension,
diabetes mellitus, hypercholesterolemia, coronary artery
disease, peripheral vascular disease, and atrial ﬁbrillation.2 Gastroenterology Research and Practice
Thechronologicalrelation betweensorafenibadministration
and the CVA was also evaluated.
2.CasePresentation
The ﬁrst patient is a 66 year-old Caucasian male who was
diagnosed with well-diﬀerentiated HCC in a background
of cirrhosis in April 2009. Serology was found positive for
hepatitis C, butunaware of the infection. He was had an oth-
erwise unremarkable medical history, he was an ex-smoker
(55 pack-years), and was receiving no medication. Based
on the presence of vascular invasion and his impaired liver
function, the disease was classiﬁed as stage C HCC according
to the Barcelona Clinic Liver Cancer (BCLC) staging system.
He was started on sorafenib at a dose of 400mg twice daily.
Within a month of starting sorafenib, he presented with
left facial droop, slurred speech, and left upper extremity
weakness. His platelet count was 63,000/mm3 and the rest
of the laboratory tests were noncontributory.
The second patient is a 75 year-old non-smoker Cau-
casian male diagnosed with HCC with serology negative for
hepatitis B and C. His medical history was unremarkable
exceptfor being diagnosed with stage IIIcolon cancer2years
beforeandhavingreceivedadjuvantFOLFOXtreatment.The
only possible HCC risk factor in the patient’smedical history
was his exposure to chemical substances while working in
plastics industry for many years. Biopsy of the hepatic lesion
revealed that it was a second primary malignancy and not a
hepatic metastasis from the treated colon cancer. Based on
his performance status and the presence of vascular invasion,
he was diagnosed with stage C HCC. While on single-
agent sorafenib for about 5 weeks at 400mg twice a day,
he presented with confusion, left facial drooping, garbled
speech, and urinary incontinence. The platelet count was
366,000/mm3.
Neither patient had developed hypertension while on
sorafenib nor were they overweight. The head com-
puted tomography (CT) scan was performed with con-
trast medium in both patients and did not reveal acute
abnormalities in either one. Nohemodynamically signiﬁcant
stenosis was visible in the carotid ultrasound, and the
echocardiogram showed normal size of the heart chambers
and normal systolic function of the left ventricle. Sorafenib
was discontinued in both cases. Neither patient recovered
fully from their neurological symptoms. The acute onset of
symptomsaswell asthefact thatthelatterpartially improved
with no steroid administration support the notion that the
neurological presentation was attributed to CVA and not
brain metastases. Later on, this was also conﬁrmed in one
of the two patients with a brain MRI.
3.Discussion
Recent advances in the molecular biology of cancer have
led to the introduction of antiangiogenic biologic agents,
such as bevacizumab, sunitinib, and sorafenib into clinical
trials as well as into clinical setting. These drugs seem to be
associated with increased risk of bleeding and arterial and
venous thromboembolic events [7].
HCC is characterized by the activation of the Raf/MEK
/EPK pathway and is a highly angiogenic malignancy. It
has been found that multiple factors, such as EGFR, VEGF,
and hepatitis C virus, are implicated in the activation of
this pathway [8]. Apart from the fact that cerebrovascular
eventsare generallymorecommon in cancerpatients[9],the
association between HCC and risk of CVA has been poorly
studied. Metabolic syndrome is a strong risk factor for HCC
even in nonﬁbrotic liver and is related to underlying vascular
pathology [10]. However, our two patients were not charac-
terized by central obesity, they were not diabetic and their
lipidemic proﬁle was within normal range. Furthermore,
ultrasound revealed no signiﬁcant carotid disease. Therefore,
neither patient had additional risk factors for CVA, other
than their gender and the age factor in the second patient.
The mechanism, by which sorafenib may cause CVA, is
not clear, but multiple pathways may be implicated. Firstly,
the inhibition of VEGF by sorafenib disrupts the regener-
ation of endothelial cells causing vascular wall defects and,
thereby, the possibility of thrombosis is increased [7]. The
production of nitric oxide is also reduced by the inhibition
of VEGF, whereas platelet activation and degranulation are
induced [11]. CVA during sorafenib treatment may also
be associated with uncontrolled hypertension [12], but this
was not the case in our two patients. Drug-related cardiac
arrhythmias (i.e., atrial ﬁbrillation) could be an underlying
causeforacutecerebralevents,but,sofar,arrhythmia hasnot
been reported in the safety proﬁle of sorafenib [6]. Finally,
concurrent chemotherapy mayincrease therisk for CVA [13]
but in our cases, the CVA developed while the patients were
on sorafenib monotherapy.
These two cases suggestthe need forcareful evaluationof
a patient’s individual risk for CVA before sorafenib is started
and for close monitoring thereafter. Physicians must be alert
in orderto detecthemostaticcomplicationsandneurological
symptoms, andtheyshouldconsiderdiscontinuingsorafenib
promptly in absence of other risk factors. Further studies
are required to better understand the pathophysiologic
mechanisms involved and to deﬁne a safe prophylactic
strategy. In the meantime, treatment with sorafenib should
be selected based on a beneﬁt-risk assessment.
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